NAYA Therapeutics Partners With IONETIX to Build a US Production & Supply Network for Astatine-211 Targeted Alpha Therapies
August 21st, 2025
H.C. Wainwright Immune Cell Engager Virtual Conference Presentation
June 24th, 2025
NAYA Expands its HCC Pipeline With First-in-Class GPC3-Targeted Astatine-211 Alpha Radioimmunotherapy
June 17th, 2025
Multispecific Trial Supply Stability Hinges On CDMO Agility (BioProcess Online)
June 10th, 2025
NAYA Enters into Definitive Agreements to Regain Full Rights to Next-Gen Cancer Immunotherapies As It Advances Towards Clinical Milestones
May 29th, 2025
Scrip M&A Podcast (with NAYA CEO Daniel Teper)
May 1st, 2025
NAYA Therapeutics Corporate Presentation
August 2025
